# Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

> **NCT02371369** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 120 (actual)

## Conditions studied

- Pigmented Villonodular Synovitis
- Giant Cell Tumors of the Tendon Sheath
- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** Pexidartinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02371369
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-11
- **Primary completion:** 2017-03-27
- **Final completion:** 2021-04-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02371369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02371369, "Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02371369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*